4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Given Consensus Recommendation of “Moderate Buy” by Analysts
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the ten analysts that are presently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and seven have given a buy […]
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the ten analysts that are presently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and seven have given a buy […]
